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Our laboratory previously demonstrated that X-linked chronic granulomatous disease (X-CGD) mice develop ex-
aggerated inﬂammatory responses and form granulomas following intradermal challenge with sterile Aspergillus
fumigatus (AF) hyphae. In this study, we examined the efﬁcacy of retroviral-mediated gene transfer (RMGT) into X-
CGD bone marrow stem cells in preventing this abnormal inﬂammatory response. Sterile AF or saline was injected
subcutaneously into the ears of wild-type, female X-CGD carrier, X-CGD, or X-CGD mice chimeric for varying
numbers of either wild-type or RMGT-corrected neutrophils. Intradermal AF induced marked inﬂammation at both 3
and 30 d in the X-CGD mice, but not in the carriers or the wild-type mice. Similar to wild-type mice, chimeric X-CGD
mice with 420% oxidase-positive neutrophils displayed a minimal and self-limited inﬂammatory response. Inﬂam-
mation in chimeric (both wild-type and RMGT-corrected) mice with o15% oxidase-positive neutrophils was also
improved compared to X-CGD mice, although still abnormal. This is the ﬁrst evidence that partial correction of
NADPH oxidase activity by gene therapy is likely to be beneﬁcial in reducing or preventing the chronic inﬂam-
matory complications of CGD patients if sufﬁcient numbers of RMGT-corrected neutrophils are obtained.
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Chronic granulomatous disease (CGD) is an inherited dis-
order in which superoxide generation by the phagocyte
NADPH oxidase is absent or markedly deficient (Dinauer,
2003). This enzyme generates highly reactive oxygen spe-
cies necessary for phagocyte microbicidal activity. The
most common form of CGD is X-linked (X-CGD) and results
from mutations in the gp91phox subunit of the NADPH ox-
idase flavocytochrome. CGD patients experience recurrent
and often life-threatening bacterial and fungal infections
from a wide variety of pathogens, predominantly Staphylo-
coccus aureus, Aspergillus species, and gram-negative
enteric bacilli. Chronic inflammatory granulomas are a
distinctive hallmark of CGD, and skin granulomas are not
infrequent in CGD patients (Segal et al, 2000). Chronic in-
flammatory lesions are likely to result from a combination of
factors, including the incomplete degradation of cellular
debris, which accumulates in the absence of respiratory
burst-derived oxidants and/or a dysregulated inflammatory
response (Gallin et al, 1983; Segal, 1996; Morgenstern et al,
1997; Ottonello et al, 2002; Petersen et al, 2002; Brown
et al, 2003).
Our laboratory has established several models of gran-
ulomatous inflammation in X-CGD mice using sterilized
Aspergillus fumigatus (AF) hyphae. Intratracheal instillation
of sterilized AF into the lungs of X-CGD mice resulted in
a chronic pneumonitis with granulomatous lesions, a phe-
nomenon not observed in wild-type mice (Morgenstern
et al, 1997). More recently, we described a novel model of
cutaneous granuloma formation in murine X-CGD (Petersen
et al, 2002). X-CGD mice injected subcutaneously with
sterilized AF displayed significant acute (1–3 d) and chronic
(30 d post-injection) inflammatory responses compared
with wild-type and X-CGD carrier female mice. We pro-
posed that this model may prove useful as a functional test
to evaluate the efficacy of gene therapy protocols being
developed for CGD.
Since CGD results from a mutation in a single gene in
hematopoietic stem cells, it represents a candidate target
disease for hematopoietic cell gene replacement therapy.
Gene therapy for CGD could conceivably provide sufficient
NADPH oxidase-reconstituted neutrophils to overcome, or
at least reduce, the infectious and granulomatous compli-
cations of CGD. Retroviral-mediated gene transfer (RMGT)
into CGD bone marrow cells has been shown, by our and
other laboratories, to successfully correct respiratory burst
oxidase activity in phagocytes in vivo and improve host
defense against fungal and bacterial pathogens in murine
models of CGD (Bjorgvinsdottir et al, 1997; Mardiney et al,
Abbreviations: AF, Aspergillus fumigatus; CGD, chronic gran-
ulomatous disease; RMGT, retroviral-mediated gene transfer;
X-CGD, X-linked CGD
Copyright r 2005 by The Society for Investigative Dermatology, Inc.
705
1997; Dinauer et al, 1999, 2001). The requirements for
phenotypic correction varied with the pathogen. In general,
more RMGT-corrected neutrophils were necessary to im-
prove host defense following bacterial challenge than fungal
challenge (Dinauer et al, 2001). The level of superoxide
production per cell appeared to be a second important
factor (Bjorgvinsdottir et al, 1997; Dinauer et al, 2001).
The efficacy of gene replacement therapy in ameliorating
the chronic granulomatous complications of CGD have not
yet been investigated. We therefore employed our model of
cutaneous inflammation to address two main questions:
First, how many RMGT-corrected neutrophils are necessary
to prevent or reduce granulomatous inflammation induced
by intradermal injection of sterile AF; and second, does the
cellular level of neutrophil NADPH oxidase activity influence
granuloma formation.
Results
Generation of chimeric RMGT-corrected and wild-type
X-CGD mice X-CGD mice which were chimeric for varying
levels of RMGT-corrected or normal neutrophils were gen-
erated by marrow transplantation, and the fraction of ox-
idase-positive neutrophils in each mouse determined by
peripheral blood nitroblue tetrazolium (NBT) testing (Dinauer
et al, 1999), a highly sensitive qualitative assay for NADPH
oxidase activity. Note that wild-type neutrophils exhibit at
least 3-fold more NADPH oxidase activity on a per-cell basis
than MSCV-m91Neo-corrected neutrophils, as determined
using a quantitative assay (Dinauer et al, 1999). Chimeric
mice were stratified into groups based on the percentage of
oxidase-positive neutrophils, as shown in Table I.
Acute phase (3 d) response to intradermal AF injec-
tion Three days after injection with 2.5 mg sterile AF or
phosphate-buffered saline (PBS), ears were examined for
clinical evidence of inflammation, as assessed by ear ery-
thema and/or edema (Table I). No inflammation was ob-
served in wild-type, carrier or X-CGD ears injected with
PBS. As previously shown (Petersen et al, 2002), a 2.5 mg
dose of AF did not elicit a response in the wild-type or
carrier mice, but did so in all X-CGD mice. Only one of 12
chimeric mice with 420% oxidase-positive neutrophils,
and none of the wild-type or carrier mice, showed any vis-
ible or palpable signs of inflammation 3 d after AF injection
(po0.0001, X-CGD vs chimeric mice with 420% oxidase-
positive neutrophils). In contrast, 11 of 16 chimeric mice
with o15% oxidase-positive neutrophils displayed acute
inflammation of the AF-injected ear (Table I). The reduced
incidence of clinical inflammation at 3 d between the group
of X-CGD and chimeric mice with o15% oxidase-positive
neutrophils approached statistical significance (p¼0.0525).
The degree of ear inflammation 3 d after AF injection was
quantitated by measuring the ear thickness (Fig 1A). As
before (Petersen et al, 2002), X-CGD mice exhibited a  2-
fold increase in ear thickness 3 d after AF injection, whereas
the ear thickness of wild-type mice and carrier females was
unaffected. Chimeric mice with 420% NBT-positive ne-
utrophils showed no increase in ear thickness (pp0.008,
chimeras vs X-CGD mice). In contrast, RMGT-corrected
chimeric mice with o15% NBT-positive neutrophils still
displayed a substantial increase in ear thickness at 3 d
compared to wild-type control mice (p¼ 0.0004). This
measure of acute inflammation was slightly reduced com-
pared to X-CGD mice, particularly in wild-type chimeras
with o15% oxidase-positive neutrophils, which ap-
proached statistical significance compared to X-CGD mice
Table I. Mouse groupings and inﬂammatory reponses to intradermal sterile AF challenge
Genotype N
% oxidase
þPMN Range
Oxidase
þPMN
(  103)
Range
(# tested)
Inﬂammation
at 3 d
Inﬂammation
at 30 d
Inﬂammation
by histology
Histologic
grading
WT 10 100 ND 2.3  1.3 1.3–3.2 (2) 0/10 0/10 0/10 0  0
Carriers 6  50 ND 1.2  0.4 0.9–1.9 (5) 0/6 0/5 0/5 0  0
X-CGD 12 0 ND 0 0 (2) 12/12a 12/12a 6/6 2.7  1
Chimeras
GTc 20%–35% 4 29.5  2.4 26–31 ND ND 0/4b 0/4b 0/4b 0  0
GTc435% 4 54.5  8.5 43–61 ND ND 0/4b 0/4b 0/4b 0  0
WTc 20%–35% 4 27.8  5.3 22–34 ND ND 1/4b 1/4b 1/4b 0.25  0.5
GTco15% 12 10.2  3.4 4–15 0.3  0.2 0.05–0.6 (10) 9/12c 10/12c 1.4  0.9
WTco15% 4 11  4.2 6–16 0.3  0.1 0.2–0.4 (4) 2/4c 2/4c 4/4 1.5  0.6
RMGT-corrected and wild-type chimeric X-CGD mice were categorized by percentage of oxidase-positive neutrophils, as assessed by NBT testing.
The number of oxidase-positive (þ ) neutrophils (  103) per mL of peripheral blood was calculated by multiplying the number of neutrophils per ml of
peripheral blood by the percentage of NBT-positive neutrophils. The number of mice with clinical or histologic evidence of inflammation at 3 and 30 d, out
of the total number of mice studied in each group, are as indicated. Criteria for the presence of clinical inflammation included visible erythema, edema, or
ulceration, palpable boggy edema or presence of a firm papule/granuloma. Histologic evidence of inflammation in each biopsy specimen was graded on
a 0–4þ scale, as described in the Materials and Methods.
aTotal includes six X-CGD mice from our previous work (Petersen et al, 2002).
bpp0.0001, X-CGD versus group of chimeras with X20% oxidase-positive neutrophils.
cp¼ 0.0525, X-CGD versus group of chimeras with o15% oxidase-positive neutrophils.
RMGT, retroviral-mediated gene transfer; X-CGD, X-linked chronic granulomatous disease; NBT, nitroblue tetrazolium; PMN, polymorphonuclear
leukocytes; ND, not done; GTc, gene therapy chimera; WTc, wild-type chimera; WT, wild-type.
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(p¼0.057). This suggests that the higher amount of super-
oxide produced per cell in wild type chimeras may reduce
the degree of acute inflammation in this model.
Chronic phase (30 d) response to intradermal AF injec-
tion We next examined whether an inflammatory response
was present 30 d after intradermal AF challenge. Three
measures of chronic inflammation were assessed: gross
examination; punch biopsy thickness and weight; and his-
tology (Table I). In all X-CGD mice examined, a firm papule
was palpable in the AF-injected ear, which was large, ery-
thematous and ulcerated in some mice. No evidence of in-
flammation was palpable in the ears of wild-type or carrier
mice injected with 2.5 mg of AF, as also reported previously
(Petersen et al, 2002). A tiny, nonulcerated papule was pal-
pable in the ear of one of the wild-type chimeric mice with
25% NBT-positive neutrophils. None of the RMGT-corrected
chimeras with 420% NBT-positive neutrophils displayed
clinical evidence of chronic inflammation (p¼ 0.0001, chi-
meric vs X-CGD mice). In comparison, a small nonulcerated
papule was evident in nine of 12 RMGT-corrected chimeras
with o15% NBT-positive neutrophils, and in two of four
wild-type chimeras with o15% NBT-positive neutrophils
(Table I). The reduced incidence of inflammation in chimeric
mice with o15% oxidase-positive neutrophils compared
with X-CGD mice approached but did not quite reach sta-
tistical significance (p¼ 0.0525).
Chimeric mice with 420% NBT-positive neutrophils
showed no significant difference in ear thickness compared
to wild-type mice at 30 d, in contrast to the substantial
increase in ear thickness that persisted in X-CGD mice
(pp0.03; Fig 1B). At 30 d, however, ear thicknesses of both
the wild-type and RMGT-corrected chimeras with o15%
oxidase-positive neutrophils were still significantly greater
than wild-type mice (p¼ 0.0003 and 0.014, respectively).
The biopsy specimen weights mirrored the thickness meas-
urements, as shown in Fig 1C). Chimeric mice with 420%
NBT-positive neutrophils showed no significant increase in
biopsy weight compared with wild-type mice at 30 d. In
contrast, the biopsy weights of both the RMGT-corrected
and wild-type chimeras with o15% oxidase-positive ne-
utrophils were significantly greater than the wild-type con-
trols (p¼0.0006 and 0.008, respectively). Biopsy weights
were modestly decreased compared to the X-CGD controls,
which approached statistical significance (p¼ 0.08 and
0.27, respectively).
Histologic specimens obtained 30 d after AF injection
were examined for the presence or absence of chronic in-
flammation, and the extent of the inflammation was graded
as described in the Materials and Methods. Results are
shown in Table I, and representative photomicrographs are
shown in Fig 2. Ears of wild-type mice injected 30 d pre-
viously with AF had a normal histologic appearance (Fig 2A).
In marked distinction is a section of AF-injected X-CGD ear
(Fig 2B), which shows a striking chronic inflammatory reac-
tion with both neutrophil and mononuclear cell infiltration,
as well as areas of granuloma formation, as described in our
prior study (Petersen et al, 2002). The degree of inflamma-
tion ranged from 2þ to 4þ in the six X-CGD mice scored,
with two mice having a score of 4þ inflammation. A re-
duced but still discernable chronic inflammatory process
Figure 1
Transplantation with wild-type or gp91phox-transduced marrow
reduces the exaggerated inflammatory response in X-linked
chronic granulomatous disease (X-CGD) mice injected with intra-
dermal Aspergillus fumigatus (AF). Sterile AF (2.5 mg) and phos-
phate-buffered saline (PBS) vehicle were injected into the dorsal ears of
wild-type C57Bl6/J (WT), female X-CGD carrier (Car), X-CGD, gene
therapy-corrected chimeric X-CGD (GTc), or wild-type chimeric X-CGD
(WTc) mice, as described in Table I. Three days after injection inflam-
mation was assessed by measuring ear thickness using calipers (panel
A). Thirty days after injection the animals were sacrificed and 5 mM
punch biopsies of the injection sites were obtained; the biopsy spec-
imens were then measured for thickness (panel B) and weighed (panel
C). The data are shown as the mean  SD difference in the thickness or
weight between the control PBS- and AF-injected ears. Asterisks ()
denote a statistically significant difference between WT controls and
either X-CGD or X-CGD chimeric mice with o15% oxidase-positive
neutrophils (pp0.008, Mann–Whitney U test). Daggers (w) denote that
X-CGD chimeric mice with 420% oxidase-positive neutrophils dis-
played significantly less inflammation compared to X-CGD control mice
(pp0.04, Student’s t test).
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was present in ten of 12 RMGT-corrected chimeric mice
with o15% NBT-positive neutrophils (Fig 2C), and four of
four wild-type chimeric mice. The small reduction in the in-
cidence of histologic inflammation in the RMGT-corrected
chimeras compared to X-CGD mice was not statistically
significant (p¼ 0.53). No sections from a RMGT-corrected
chimera with o15% NBT-positive neutrophils, however,
displayed severe inflammation which warranted a score of
4þ , and only one of 12 mice of this group was assigned a
score of 3þ . All four of the o15% wild-type chimeras
demonstrated only focal inflammation, and were assigned
scores of 1þ or 2þ . In all RMGT-corrected and three of
four wild-type chimeras with 420% NBT-positive ne-
utrophils, the histologic appearance of AF-injected ears
was normal at 30 d (Table I and Fig 2D). One wild-type
chimeric mouse with 25% oxidase-positive cells had a
small papule evident 3 and 30 d post-injection, with a single
small focus of chronic inflammation upon histologic exam-
ination. There was otherwise no difference in the histologic
appearance of biopsies obtained from wild-type chimeras
versus RMGT-corrected chimeras with 420% oxidase-
positive neutrophils.
Discussion
In this study, we investigated whether reconstitution of
NADPH oxidase activity by transplantation of wild type or
gene therapy-corrected bone marrow stem cells could re-
duce chronic inflammation and granuloma formation in
murine X-CGD, using an established model in which mice
are challenged with sterile AF hyphae. Achievement of only
partial chimerism with RMGT-corrected cells is likely in the
clinical setting (Barese et al, 2004). Thus, we studied mice
with varying numbers of oxidase-corrected neutrophils. We
found that moderate numbers of RMGT-corrected ne-
utrophils (20%–35% NBT-positive) completely abrogated
sterile AF-induced cutaneous inflammation and granuloma
formation. In contrast, mice chimeric for lower levels of ei-
ther RMGT-corrected (mean 10.2%  3.4%) or wild type
(mean 11%  4.2%) neutrophils still exhibited exaggerated
acute inflammation and persistent chronic inflammatory
changes. Nevertheless, the incidence of this abnormal re-
sponse was reduced compared to X-CGD mice, although
this did not quite reach statistical significance, and the de-
gree of chronic inflammation was also less severe com-
pared to X-CGD mice, suggesting some beneficial effect.
Thus, this is the first report demonstrating that partial cor-
rection of neutrophil NADPH oxidase activity by gene trans-
fer can reduce exaggerated acute inflammation as well as
the development of chronic granulomatous lesions in CGD
(Figs 1 and 2), and defines a threshold for the percentage of
oxidase-positive neutrophils necessary to prevent the ab-
normal inflammatory response observed in this model. This
study further establishes a model system in which to study
the clinical impact of gene therapy, as well as other
immunomodulatory and anti-inflammatory strategies.
It remains unclear whether differences exist between the
inflammatory responses of X-CGD mice chimeric for wild-
type cells compared to RMGT-corrected cells, where cel-
lular oxidase activity is 3-fold lower than normal (Dinauer
et al, 1999). Mice chimeric for 420% oxidase-positive ne-
utrophils, either wild type or RMGT-corrected, lacked an
abnormal inflammatory response to intradermal AF, similar
to wild-type mice (Table I and Fig 1). We observed, however,
subtle differences in the incidence and severity of inflam-
mation 3 d after AF injection between mice chimeric for
o15% RMGT-corrected compared to chimeras with wild-
type neutrophils; no differences in these two groups, how-
ever, were evident at 30 d (Table I and Fig 1). Much larger
numbers of mice would be required in order to demonstrate
whether or not these subtle differences between wild type
and gene therapy chimeras are statistically significant.
Whereas  15% oxidase-positive (either RMGT-correct-
ed or wild-type) murine neutrophils was the threshold for
preventing AF-induced skin inflammation in this inbred
mouse model, this boundary may not precisely translate to
the human disease. The clinical severity of CGD can vary,
likely due in part to disease-modifying genes (Dinauer,
2003). For example, in human CGD patients, polymorph-
isms in other host defense genes, such as myeloperoxidase
and Fc receptor subtypes, may impact the frequency of
chronic inflammatory complications, as has been reported
for CGD patients with gastrointestinal inflammation (Foster
et al, 1998). Nonetheless, our results, combined with
Figure 2
Transplantation with wild-type or gp91phox-transduced marrow
reduces tissue inflammation and granuloma formation in X-linked
chronic granulomatous disease (X-CGD) mice injected with intra-
dermal (AF). Sterile AF (2.5 mg) and phosphate-buffered saline (PBS)
vehicle were injected into the dorsal ears of wild-type C57Bl6/J, female
X-CGD carrier, X-CGD, gene therapy-corrected chimeric X-CGD, or
wild-type chimeric X-CGD mice. Thirty days after injection the animals
were sacrificed and punch biopsies of the injection sites were obtained;
after biopsy thicknesses and weights were obtained (Fig 1), biopsy
specimens were processed for histologic evaluation. Panel A shows a
representative ear biopsy section, stained with hematoxylin and eosin
(H&E), from a wild-type mouse injected with AF, which displays normal
histology. Panel B is a section from an X-CGD mouse, which shows an
extensive chronic inflammatory reaction, with both neutrophilic and
mononuclear cells, and evidence of fibrotic granuloma formation, as
described previously (Petersen et al, 2002). The low-level (o15%) re-
troviral-mediated gene transfer (RMGT)-corrected chimera depicted in
panel C shows evidence of chronic inflammation, but less than the X-
CGD mouse section in panel B. Biopsies from ten of 12 low-level
RMGT-corrected chimeras showed some degree of chronic inflamma-
tion as represented here; two mice, however, displayed no inflamma-
tion by histology. The ear biopsy section from a high-level (420%)
RMGT-corrected chimera (panel D) displays normal histology, similar to
the wild-type mouse in panel A. Scale bar¼ 1250 mm.
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observations in CGD carriers and patients, outline guide-
lines for the partial correction of NADPH oxidase function
which may reduce inflammatory as well as infectious (Din-
auer et al, 2001) complications of CGD.
The means by which the lack of a respiratory burst re-
sults in increased inflammation and granuloma formation in
CGD is not well understood. AF-induced inflammation may
be due, at least in part, to the inability of the X-CGD ne-
utrophils to efficiently degrade the hyphae material. Thus,
oxidase-positive neutrophils are recruited into these lesions,
but if present in insufficient numbers, cannot prevent the
development of chronic lesions. Preliminary studies AF-in-
duced chronic inflammatory skin lesions in X-CGD mice
chimeric for small numbers of wild-type neutrophils indicate
that the vast majority of neutrophils within the lesion are
oxidase-negative (unpublished observations). Decreased
apoptosis of CGD neutrophils (Ottonello et al, 2002; Brown
et al, 2003), and increased levels of inflammatory mediators
such as leukotriene B4 (Petersen et al, 2002; Segal et al,
2002), may also contribute to an abnormal inflammatory
response.
The sterile AF challenge model presented here may be
specific only for pathogen-induced inflammation, and may
not reproduce other aspects of CGD inflammation. To our
knowledge, however, no other models of chronic gran-
ulomatous inflammation have been established using either
the gp91phox- or p47phox-deficient CGD mice. The relation-
ship of this model to the cutaneous lesions observed in
women who are X-CGD carriers is also uncertain. Female
carriers of X-CGD who, on average, have  50% oxidase-
positive neutrophils, can exhibit a variety of skin manifes-
tations, most commonly discoid lupus erythematosus-like
lesions (reviewed in Dohil et al (1997) and Rupec et al
(2000)). The pathogenesis of cutaneous lupus-like lesions in
X-CGD carriers remains poorly understood, but it has been
suggested that persistence of poorly degraded material
may lead to aberrant activation of systemic immune, or
even autoimmune, pathways (Rupec et al, 2000). It appears,
however, that the etiology of the discoid lupus-like lesions
differs from CGD granuloma formation, since female carri-
ers of X-CGD do not develop granulomas. Moreover, if the
persistence of poorly degraded material was the sole
mechanism leading to discoid lupus-like lesions in CGD
carriers, one would expect that CGD patients would devel-
op discoid lupus-like lesions in greater number or in more
severe forms than carriers, which they do not.
Further work is needed to elucidate the underlying
mechanisms that contribute to the abnormal inflammation
characteristic of chronic granulomatous disease, which may
reveal novel means to downregulate the vigorous and per-
sistent CGD inflammatory response and reduce patient
morbidity. This work, however, clearly demonstrates that
partial correction of phagocyte NADPH oxidase activity in a
minority of cells by RMGT can be sufficient to reduce or
prevent abnormal inflammatory responses in X-CGD.
Materials and Methods
Mice X-CGD (gp91phox/) and carrier female (gp91phox/þ ) mice
used in this study were backcrossed into the C57Bl6/J strain (Pol-
lock et al, 1995; Dinauer et al, 1999). Wild-type C57Bl6/J mice
(Jackson Lab, Bar Harbor, Maine) were maintained under patho-
gen-free conditions, and were fed autoclaved food and acidified
water ad libitum. All protocols were approved by the institutional
animal use and care committee at Indiana University School of
Medicine.
Transduction of X-CGD bone marrow cells and transplantation
of mice X-CGD marrow isolation, transduction with the MSCV-
m91Neo retroviral vector and transplantation of X-CGD hosts with
X-CGD or wild-type marrow cells was performed as described
previously as per approved institutional protocols (Bjorgvinsdottir
et al, 1997; Dinauer et al, 2001). X-CGD hosts were transplanted
with a total of 2–3  106 marrow cells by tail vein injection using
either MSCV-m91Neo-transduced X-CGD marrow cells (to gener-
ate high-level RMGT-corrected chimeric mice), mixtures of MSCV-
m91Neo-transduced X-CGD marrow cells and fresh X-CGD mar-
row cells (low-level RMGT-corrected chimeric mice), or mixtures of
wild-type C57Bl6/J and X-CGD marrow cells (wild-type chimeric
mice). NADPH oxidase-positive neutrophils in chimeric X-CGD
hosts were monitored by NBT (Sigma, St Louis, Missouri) testing of
peripheral blood (Dinauer et al, 1999) on at least two occasions
within 3 wk of sterile AF injection. Transplanted hosts were typically
4–6 mo post-transplant at the time of AF injection, and were paired
with similarly aged control mice.
Subcutaneous injections and measurement of inﬂammation
and granuloma formation Intradermal injections of sterilized AF
hyphae were performed as described (Petersen et al, 2002). Mice
were anesthetized with intraperitoneal Avertin (2.5% vol/vol in
0.9% NaCl, 0.015–0.025 mL per g body weight), and the dorsal
aspect of one ear was injected with 50 mL of a solution containing
2.5 mg of AF, with the contralateral ear injected with PBS vehicle. At
3 and 30 d post-injection, all mice were examined for clinical
evidence of inflammation at the injection sites. Three days after
injection, ear inflammation was assessed by measuring ear
thickness using spring-loaded calipers (Mitutoyo, Aurora, Illinois).
At 30 d post-injection, the mice were sacrificed by Avertin over-
dose and CO2 asphyxiation. A 5 mm punch biopsy was then taken
of each ear, and each biopsy was weighed, measured for thick-
ness, and processed for histologic evaluation. Biopsy specimens
were evaluated for the presence or absence of inflammatory cells,
and were graded on a 0–4þ scale, with a score of 0 indicating no
inflammation (e.g., as seen in ears injected with PBS), and a score
of 4 denoting maximum inflammation observed in X-CGD controls,
with the specimen being more than 2-fold thicker than a PBS-
injected ear, with a neutrophil and chronic inflammatory cell infil-
trate (with or without granuloma formation) present throughout the
entire biopsy specimen. A minimum of four sections per biopsy
specimen were examined and scored.
Statistical analyses InStat Version 3.05 for Windows (GraphPad
Software, San Diego, California; www.graphpad.com) was used for
all statistical analyses. The data are given as mean  SD. The un-
paired Student’s t test (with or without Welch correction for unequal
SD) was used for comparison of clinical observations (e.g., ear
thickness and weight measurements) if the software calculated
that the data were normally distributed; if not, the nonparametric
Mann-Whitney U test was utilized. Fisher’s exact test was used to
determine if the incidence of inflammation between groups was
significant.
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